According to reports, BioMap, a life sciences artificial intelligence (AI) large model company, has confidentially submitted an application for a Hong Kong listing and plans to raise several billion U.S. dollars. The reports indicate that BioMap is working with China International Capital Corporation, Morgan Stanley, and UBS Group on the preparation for this listing. However, related discussions are still ongoing, and details such as the fundraising scale and listing timeline are subject to change. BioMap was jointly founded in 2020 by Baidu co-founder and CEO Robin Li and former Baidu Ventures CEO Wei Liu. The current CEO of BioMap, Wei Liu, stated last May that the company planned to seek a listing in Hong Kong within the next year and a half. Information shows that BioMap, as a pioneer in global foundational large models for life sciences, utilizes a 210-billion-parameter cross-modal biological language model to decode the underlying principles of genomes, proteins, cells, and biological systems, enabling the construction of high-quality life sciences AI task models with less data and lower costs.